NCT06702774 Research on Key Interventional Technologies for Controlling the Epidemic in High-prevalence Areas of Tuberculosis in Guangxi, China
| NCT ID | NCT06702774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Toronto |
| Condition | Tuberculosis (TB) |
| Study Type | INTERVENTIONAL |
| Enrollment | 72,000 participants |
| Start Date | 2021-11-20 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72,000 participants in total. It began in 2021-11-20 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to find out if using mobile vans with advanced technology can help reduce tuberculosis (TB) in rural Guangxi, China. The study will also examine how practical and cost-effective this approach is. The main questions it aims to answer are: 1) Does this new screening method lower the number of TB cases among high-risk groups? and 2) Is this method practical and acceptable for communities and healthcare workers? Participants in the study will: 1) undergo TB screening with mobile vans that use artificial intelligence (AI) to read chest X-rays, 2) answer a short questionnaire about their symptoms and health history, and 3) provide sputum samples for GeneXpert testing if needed. Some communities will receive the new screening method, while others will continue with usual care. Researchers will compare TB rates in the two groups over three years to see if the new approach works better for TB control. If successful, this method could be used to improve TB control in other areas.
Eligibility Criteria
Inclusion Criteria: * all residents who are elderly (i.e., aged 65 and above) * all residents who are aged 15 to 64 with one of the following conditions: being patients previously treated for TB or close contacts of a patient with a TB patient diagnosed within the last three years; having been clinically diagnosed with diabetes, HIV positive, or worked as a miner * Have signed consent form Exclusion Criteria: * Residents who refuse participation.
Contact & Investigator
Dabin Liang, PhD
PRINCIPAL INVESTIGATOR
Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
Frequently Asked Questions
Who can join the NCT06702774 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Tuberculosis (TB). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06702774 currently recruiting?
Yes, NCT06702774 is actively recruiting participants. Contact the research team at gxmu958@163.com for enrollment information.
Where is the NCT06702774 trial being conducted?
This trial is being conducted at Nanning, China.
Who is sponsoring the NCT06702774 clinical trial?
NCT06702774 is sponsored by University of Toronto. The principal investigator is Dabin Liang, PhD at Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control. The trial plans to enroll 72,000 participants.